ArticleDiscover nano2025
A curcumin-enabled ZIF8 nanosystem enables ovarian cancer treatment by inducing mitochondrial disruption.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a common malignancy affecting the female reproductive system. Curcumin (Cur) demonstrates potential as a treatment for ovarian cancer, but creating an effective curcumin-based drug delivery system remains challenging. The advent of the Zeolitic Imidazolate Framework (ZIF) system offers a novel approach for antitumor drug delivery. In this study, effective drug delivery to ovarian cancer cells was accomplished through the construction of a ZIF-based nanodrug delivery system, ZIF-Cur, that encapsulates curcumin. We verified that Cur delivered by ZIF enhanced mitochondrial ROS accumulation in tumor cells, thereby killing tumor cells. The system showed the well biosafety profile, offering a insight therapeutic perspective for ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.